242 related articles for article (PubMed ID: 29191714)
1. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial.
Vacca A; Melaccio A; Sportelli A; Solimando AG; Dammacco F; Ria R
Clin Immunol; 2018 Jun; 191():110-115. PubMed ID: 29191714
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
Compagno N; Cinetto F; Semenzato G; Agostini C
Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
[TBL] [Abstract][Full Text] [Related]
3. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
[TBL] [Abstract][Full Text] [Related]
4. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.
Ochs HD; Gupta S; Kiessling P; Nicolay U; Berger M;
J Clin Immunol; 2006 May; 26(3):265-73. PubMed ID: 16783465
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.
Thépot S; Malphettes M; Gardeur A; Galicier L; Asli B; Karlin L; Gérard L; Laumont R; Doize ML; Arnulf B; Fieschi C; Bengoufa D; Oksenhendler E
J Clin Immunol; 2010 Jul; 30(4):602-6. PubMed ID: 20393788
[TBL] [Abstract][Full Text] [Related]
8. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
9. Nuts and Bolts of Subcutaneous Therapy.
Duff C; Ballow M
Immunol Allergy Clin North Am; 2020 Aug; 40(3):527-537. PubMed ID: 32654697
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
Front Immunol; 2021; 12():670547. PubMed ID: 34012453
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
[TBL] [Abstract][Full Text] [Related]
12. Secondary hypogammaglobulinemia in Waldmann's disease treated with subcutaneous immunoglobulins.
Patuzzo G; Tinazzi E; Micheletti M; Puccetti A; Lunardi C
Eur Ann Allergy Clin Immunol; 2016 Mar; 48(2):55-7. PubMed ID: 26934740
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients.
Shankar T; Gribowicz J; Crespo M; Silveira FP; Pilewski J; Petrov AA
Int Immunopharmacol; 2013 Apr; 15(4):752-5. PubMed ID: 23499641
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.
Harbo T; Andersen H; Hess A; Hansen K; Sindrup SH; Jakobsen J
Eur J Neurol; 2009 May; 16(5):631-8. PubMed ID: 19236457
[TBL] [Abstract][Full Text] [Related]
15. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
Gardulf A; Andersen V; Björkander J; Ericson D; Frøland SS; Gustafson R; Hammarström L; Jacobsen MB; Jonsson E; Möller G
Lancet; 1995 Feb; 345(8946):365-9. PubMed ID: 7845120
[TBL] [Abstract][Full Text] [Related]
17. [Immunoglobulin therapy of primary humoral immunologic deficiencies].
Bordigoni P
Rev Prat; 2007 Oct; 57(15):1691-8. PubMed ID: 18080428
[TBL] [Abstract][Full Text] [Related]
18. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
19. Nonsecretory multiple myeloma.
Rubio-Felix D; Giralt M; Giraldo MP; Martinez-Peñuela JM; Oyarzabal F; Sala F; Raichs A
Cancer; 1987 May; 59(10):1847-52. PubMed ID: 3828953
[TBL] [Abstract][Full Text] [Related]
20. The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.
Waldmann TA; Broder S; Krakauer R; MacDermott RP; Durm M; Goldman C; Meade B
Fed Proc; 1976 Jul; 35(9):2067-72. PubMed ID: 1084293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
